Quantitative Assessment of CYP2C9 Genetic Polymorphisms Effect on the Oral Clearance of S-Warfarin in Healthy Subjects

被引：0
|
作者：
Chanan Shaul
Simcha Blotnick
Mordechai Muszkat
Meir Bialer
Yoseph Caraco
机构：
[1] Hadassah-Hebrew University Medical Center,Clinical Pharmacology Unit, Division of Medicine
[2] Hebrew University,Institute of Drug Research, School of Pharmacy, Faculty of Medicine
来源：
Molecular Diagnosis & Therapy | 2017年 / 21卷
关键词：
Warfarin; Variant Allele; Warfarin Dose; Oral Clearance; CYP2C9 Genotype;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：75 / 83
页数：8
相关论文
共 50 条
  • [31] CYP2C9 polymorphisms and CYP2C9*2 genotyping primers
    Goldstein, JA
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (04) : 409 - 410
  • [32] The influence of coagulation factor and CYP2C9 polymorphisms on warfarin dose
    Aquilante, CL
    Yarandi, HN
    Langaee, TY
    Tromberg, JS
    Lopez, LM
    Waddell, CD
    Johnson, JA
    CIRCULATION, 2003, 108 (17) : 424 - 424
  • [33] CYP2C9 polymorphisms and haplotypes: correlation with warfarin dose and metabolism
    King, BP
    Khan, TI
    Kamali, F
    Daly, AK
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (05) : 639 - 639
  • [34] Warfarin: CYP2C9 polymorphisms increase risk of bleeding events
    Reactions Weekly, 2002, 897 (1) : 4 - 4
  • [35] Novel CYP2C9 polymorphisms and their relationship to warfarin dose requirements
    King, BP
    Khan, T
    Kamali, F
    Daly, AK
    DRUG METABOLISM REVIEWS, 2003, 35 : 133 - 133
  • [36] Novel CYP2C9 genetic polymorphisms and assessment of their impact on hydroxylation capacity
    Dorado, Pedro
    Penas-LLedo, Eva M.
    LLerena, Adrian
    PHARMACOGENOMICS, 2014, 15 (03) : 261 - 262
  • [37] Impacts of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide in Chinese subjects
    Zhang, Yifan
    Chen, Xiaoyan
    Lin, Nan
    Zhong, Dafang
    Si, Dayong
    Gu, Yingjie
    Zhou, Hui
    DRUG METABOLISM REVIEWS, 2006, 38 : 161 - 162
  • [38] Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose
    Zhao, F
    Loke, C
    Rankin, SC
    Guo, JY
    Lee, HS
    Wu, TS
    Tan, T
    Liu, TC
    Lu, WL
    Lim, YT
    Zhang, Q
    Goh, BC
    Lee, SC
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (03) : 210 - 219
  • [39] Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug–drug interaction studies for CYP2C9
    Kerenaftali Klein
    Ivelina Gueorguieva
    Leon Aarons
    Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39 : 147 - 160
  • [40] Effect of a selective CYP2C9 inhibitor on the pharmacokinetics of nateglinide in healthy subjects
    Helene Sabia
    Gangadhar Sunkara
    Monica Ligueros-Saylan
    Yibin Wang
    Harold Smith
    James McLeod
    Pratapa Prasad
    European Journal of Clinical Pharmacology, 2004, 60 : 407 - 412
12345